Download
journal.pone.0089454.PDF 5,97MB
WeightNameValue
1000 Titel
  • Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease
1000 Autor/in
  1. Bhattacharya, Soumee |
  2. Haertel, Christin |
  3. Maelicke, Alfred |
  4. Montag, Dirk |
1000 Erscheinungsjahr 2014
1000 LeibnizOpen
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2014-02-21
1000 Erschienen in
1000 Quellenangabe
  • 9(2): e89454
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2014
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1371/journal.pone.0089454 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931790/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • The plant alkaloid galantamine is an established symptomatic drug treatment for Alzheimer’s disease (AD), providing temporary cognitive and global relief in human patients. In this study, the 5X Familial Alzheimer’s Disease (5XFAD) mouse model was used to investigate the effect of chronic galantamine treatment on behavior and amyloid β (Aβ) plaque deposition in the mouse brain. Quantification of plaques in untreated 5XFAD mice showed a gender specific phenotype; the plaque density increased steadily reaching saturation in males after 10 months of age, whereas in females the density further increased until after 14 months of age. Moreover, females consistently displayed a higher plaque density in comparison to males of the same age. Chronic oral treatment with galantamine resulted in improved performance in behavioral tests, such as open field and light-dark avoidance, already at mildly affected stages compared to untreated controls. Treated animals of both sexes showed significantly lower plaque density in the brain, i.e., the entorhinal cortex and hippocampus, gliosis being always positively correlated to plaque load. A high dose treatment with a daily uptake of 26 mg/kg body weight was tolerated well and produced significantly larger positive effects than a lower dose treatment (14 mg/kg body weight) in terms of plaque density and behavior. These results strongly support that galantamine, in addition to improving cognitive and behavioral symptoms in AD, may have disease-modifying and neuroprotective properties, as is indicated by delayed Aβ plaque formation and reduced gliosis.
1000 Sacherschließung
lokal Entorhinal cortex
lokal Genetically modified animals
lokal Hippocampus
lokal Mouse models
lokal Astrocytes
lokal Animal behavior
lokal Mice
lokal Alzheimer disease
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/creator/QmhhdHRhY2hhcnlhLCBTb3VtZWUg|https://frl.publisso.de/adhoc/creator/SGFlcnRlbCwgQ2hyaXN0aW4g|https://frl.publisso.de/adhoc/creator/TWFlbGlja2UsIEFsZnJlZA==|http://orcid.org/0000-0002-4964-1330
1000 Label
1000 Förderer
  1. German Ministry for Education and Research (BMBF) |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. KMU-Innovativ-2
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer German Ministry for Education and Research (BMBF) |
    1000 Förderprogramm KMU-Innovativ-2
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6402841.rdf
1000 Erstellt am 2017-06-06T12:46:05.844+0200
1000 Erstellt von 23
1000 beschreibt frl:6402841
1000 Bearbeitet von 218
1000 Zuletzt bearbeitet Wed Dec 02 11:48:18 CET 2020
1000 Objekt bearb. Wed Dec 02 11:48:18 CET 2020
1000 Vgl. frl:6402841
1000 Oai Id
  1. oai:frl.publisso.de:frl:6402841 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source